$swkh 2022 Q3 10-Q

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$13.61M	$6.942M	$11.13M
YoY Change	42.41%	-68.82%	18.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.349M	$3.018M	$3.160M
YoY Change	21.48%	-10.18%	9.34%
% of Gross Profit
Research & Development	$1.792M	$1.480M	$1.901M
YoY Change	-27.95%	-4.02%	22.65%
% of Gross Profit
Depreciation & Amortization	$634.0K	$626.0K	$704.0K
YoY Change	-21.92%	-23.0%	-58.1%
% of Gross Profit
Operating Expenses	$1.792M	$1.480M	$5.765M
YoY Change	-73.95%	-4.02%	-5.65%
Operating Profit	$6.757M	$1.738M
YoY Change	157.12%	-89.53%
Interest Expense	$82.00K	$80.00K	-$801.0K
YoY Change	9.33%	-14.89%	-174.86%
% of Operating Profit	1.21%	4.6%
Other Income/Expense, Net
YoY Change
Pretax Income	$8.558M	$747.0K	$4.565M
YoY Change	210.52%	-95.73%	5.43%
Income Tax	$1.942M	$182.0K	$1.087M
% Of Pretax Income	22.69%	24.36%	23.81%
Net Earnings	$6.616M	$565.0K	$3.478M
YoY Change	194.96%	-95.96%	2.63%
Net Earnings / Revenue	48.6%	8.14%	31.25%
Basic Earnings Per Share	$0.52	$0.04	$0.27
Diluted Earnings Per Share	$0.51	$0.04	$269.9K
COMMON SHARES
Basic Shares Outstanding	12.83M shares	12.84M shares	12.83M shares
Diluted Shares Outstanding	12.85M shares	12.89M shares	12.89M shares

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.90M	$55.61M	$42.41M
YoY Change	-7.04%	514.83%	1015.92%
Cash & Equivalents	$19.40M	$55.12M	$41.40M
Short-Term Investments	$500.0K	$487.0K	$1.006M
Other Short-Term Assets	$1.189M	$1.366M	$1.576M
YoY Change	7.99%	19.2%	57.6%
Inventory
Prepaid Expenses
Receivables	$7.384M	$1.869M	$1.979M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.47M	$58.84M	$45.96M
YoY Change	14.99%	358.65%	-78.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.945M	$6.071M	$5.991M
YoY Change	2.66%	6.21%	8.93%
Goodwill	$8.404M	$8.404M
YoY Change
Intangibles	$8.615M	$9.042M
YoY Change
Long-Term Investments	$3.579M	$3.589M	$3.597M
YoY Change	-2.98%	-3.03%	-2.78%
Other Assets	$1.802M	$1.858M	$24.25M
YoY Change	-93.41%	-93.38%	-21.76%
Total Long-Term Assets	$263.8M	$225.6M	$240.0M
YoY Change	4.74%	-13.23%	297.33%
TOTAL ASSETS
Total Short-Term Assets	$28.47M	$58.84M	$45.96M
Total Long-Term Assets	$263.8M	$225.6M	$240.0M
Total Assets	$292.3M	$284.4M	$286.0M
YoY Change	5.66%	4.25%	3.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.746M	$2.776M	$4.863M
YoY Change	5.61%	-9.72%	21.58%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.746M	$2.776M	$4.863M
YoY Change	5.42%	-9.72%	-68.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.544M	$1.589M	$10.29M
YoY Change	-86.51%	-86.2%	-42.53%
Total Long-Term Liabilities	$1.544M	$1.589M	$10.29M
YoY Change	-86.51%	-86.2%	-42.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.746M	$2.776M	$4.863M
Total Long-Term Liabilities	$1.544M	$1.589M	$10.29M
Total Liabilities	$14.82M	$12.90M	$15.15M
YoY Change	-7.09%	-11.61%	-54.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.154B	-$4.160B
YoY Change
Common Stock	$13.00K	$13.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$277.4M	$271.5M	$270.8M
YoY Change
Total Liabilities & Shareholders Equity	$292.3M	$284.4M	$286.0M
YoY Change	5.66%	4.25%	3.16%

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$6.616M	$565.0K	$3.478M
YoY Change	194.96%	-95.96%	2.63%
Depreciation, Depletion And Amortization	$634.0K	$626.0K	$704.0K
YoY Change	-21.92%	-23.0%	-58.1%
Cash From Operating Activities	$1.712M	-$860.0K	$4.255M
YoY Change	-55.21%	-105.78%	-2.63%
INVESTING ACTIVITIES
Capital Expenditures	-$83.00K	-$53.00K	-$58.00K
YoY Change	-59.71%	-84.9%	-81.88%
Acquisitions
YoY Change
Other Investing Activities	-$36.59M	$14.63M	-$5.653M
YoY Change	-535.79%	89.46%	16.56%
Cash From Investing Activities	-$36.67M	$14.58M	-$5.711M
YoY Change	-547.77%	97.76%	10.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-759.0K	0.000	-8.000K
YoY Change	-9587.5%	-100.0%	-98.67%
NET CHANGE
Cash From Operating Activities	1.712M	-860.0K	4.255M
Cash From Investing Activities	-36.67M	14.58M	-5.711M
Cash From Financing Activities	-759.0K	0.000	-8.000K
Net Change In Cash	-35.72M	13.72M	-1.464M
YoY Change	-397.16%	173.78%	4.57%
FREE CASH FLOW
Cash From Operating Activities	$1.712M	-$860.0K	$4.255M
Capital Expenditures	-$83.00K	-$53.00K	-$58.00K
Free Cash Flow	$1.795M	-$807.0K	$4.313M
YoY Change	-55.44%	-105.3%	-8.04%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001089907
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther		usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	swkh	Change In Fair Value Of Acquisitionrelated Contingent Consideration ChangeInFairValueOfAcquisitionrelatedContingentConsideration		usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9964000	usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39184
	dei	Entity Registrant Name EntityRegistrantName	SWK Holdings Corporation
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0435679
	dei	Entity Address Address Line1 EntityAddressAddressLine1	14755 Preston Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 105
	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75254
	dei	City Area Code CityAreaCode	(972)
	dei	Local Phone Number LocalPhoneNumber	687-7250
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12828704	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55118000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42863000	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1869000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1803000	usd
CY2022Q2	us-gaap	Marketable Securities MarketableSecurities	487000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	1034000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1366000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1727000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	58840000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	47427000	usd
CY2022Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	174859000	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	181553000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	98000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	119000	usd
CY2022Q2	us-gaap	Cost Method Investments CostMethodInvestments	3491000	usd
CY2021Q4	us-gaap	Cost Method Investments CostMethodInvestments	3491000	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	19281000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	20539000	usd
CY2022Q2	swkh	Warrant Assets WarrantAssets	2481000	usd
CY2021Q4	swkh	Warrant Assets WarrantAssets	3419000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9042000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	8404000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8404000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6071000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5779000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1858000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1970000	usd
CY2022Q2	us-gaap	Assets Assets	284425000	usd
CY2021Q4	us-gaap	Assets Assets	282665000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2776000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5087000	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	8000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2776000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5095000	usd
CY2022Q2	swkh	Contingent Consideration Payable ContingentConsiderationPayable	8530000	usd
CY2021Q4	swkh	Contingent Consideration Payable ContingentConsiderationPayable	8530000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1589000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1804000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	12895000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	15429000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12839118	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12839118	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12836133	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12836133	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4431970000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4431719000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4160453000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4164496000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	271530000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	267236000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	284425000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	282665000	usd
CY2022Q2	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	6828000	usd
CY2021Q2	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	11805000	usd
	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	17243000	usd
	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	20484000	usd
CY2022Q2	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	114000	usd
	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	780000	usd
	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	1130000	usd
CY2021Q2	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	10461000	usd
	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	350000	usd
	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	10659000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	480000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	496000	usd
CY2022Q2	us-gaap	Revenues Revenues	6942000	usd
CY2021Q2	us-gaap	Revenues Revenues	22266000	usd
	us-gaap	Revenues Revenues	18073000	usd
	us-gaap	Revenues Revenues	31639000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	80000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	94000	usd
	us-gaap	Interest Expense InterestExpense	160000	usd
	us-gaap	Interest Expense InterestExpense	239000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1480000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1542000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3381000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3090000	usd
CY2021Q2	swkh	Change In Fair Value Of Acquisitionrelated Contingent Consideration ChangeInFairValueOfAcquisitionrelatedContingentConsideration	-147000	usd
	swkh	Change In Fair Value Of Acquisitionrelated Contingent Consideration ChangeInFairValueOfAcquisitionrelatedContingentConsideration	-147000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	626000	usd
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	811000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1330000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2493000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3018000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3360000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6178000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6245000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1738000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	16606000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	7024000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	19719000	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-472000	usd
CY2021Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	609000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1165000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	892000	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-519000	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	283000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-547000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1215000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	747000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	17498000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5312000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	21826000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	182000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3528000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1269000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4467000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	565000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	13970000	usd
	us-gaap	Profit Loss ProfitLoss	4043000	usd
	us-gaap	Profit Loss ProfitLoss	17359000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.36
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.35
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12835000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12796000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12833000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12794000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12885000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12834000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12882000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12822000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	267236000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	85000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3478000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	270799000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	166000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	565000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	271530000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	240512000	usd
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	177000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	3389000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	244078000	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	187000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	13970000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	258235000	usd
	us-gaap	Profit Loss ProfitLoss	4043000	usd
	us-gaap	Profit Loss ProfitLoss	17359000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	29000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	93000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	1257000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4369000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1165000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-892000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-547000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	1215000	usd
	swkh	Change In Fair Value Of Acquisitionrelated Contingent Consideration ChangeInFairValueOfAcquisitionrelatedContingentConsideration	-147000	usd
	swkh	Proceeds Repayment Of Finance Receivables ProceedsRepaymentOfFinanceReceivables	22779000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1599000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	26000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	251000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	364000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1330000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2493000	usd
	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	-66000	usd
	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	-728000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	256000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	477000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2526000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-813000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3395000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19250000	usd
	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	25350000	usd
	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	20100000	usd
	swkh	Proceeds Repayment Of Finance Receivables ProceedsRepaymentOfFinanceReceivables	34195000	usd
	swkh	Marketable Investment Principal Payment MarketableInvestmentPrincipalPayment	21000	usd
	swkh	Marketable Investment Principal Payment MarketableInvestmentPrincipalPayment	31000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	111000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	671000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-113000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-163000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8868000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2202000	usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-8000	usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-11758000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6083000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-17841000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12255000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3611000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42863000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3008000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55118000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6619000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zYAbFsctMHk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i><span id="xdx_86A_zAxBEVMYsiTe">Use of Estimates</span></i></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of accounts receivable; impairment of finance receivables; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</span></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	number
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	49000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	28000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12885000	shares
	swkh	Disclosure Net Income Per Share Details Abstract DisclosureNetIncomePerShareDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureNetIncomePerShareDetailsAbstract_pn3n3_zFlJ2YKt4ruc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20220401__20220630_zQ07JkLEMJt2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_494_20210401__20210630_zg7Q6WDAJIhg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20220101__20220630_zKoJ8PsfvHPk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20210101__20210630_zfeTrcmOsUE5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended <br/>June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended <br/>June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ProfitLoss_zQTbY0jcJ378" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 8.65pt">Net income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">565</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">13,970</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,043</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">17,359</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pin3_zlODqXjnc8fi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,794</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pin3_zT1ak19fL6X3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Effect of dilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pin3_zUEhB3MTHHJe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt">Weighted-average diluted shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,885</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,882</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_zSn0yeHa6jT3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_pid_zIeYSBByOFo1" style="vertical-align: bottom; background-color: White"> <td>Diluted net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Profit Loss ProfitLoss	565000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	13970000	usd
	us-gaap	Profit Loss ProfitLoss	4043000	usd
	us-gaap	Profit Loss ProfitLoss	17359000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12835000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12796000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12833000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12794000	shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	50000	shares
CY2021Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	38000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12834000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12882000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12822000	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.36
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.35
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	308000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	391000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	309000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	401000	shares
	swkh	Disclosure Finance Receivables Net Details Abstract DisclosureFinanceReceivablesNetDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureFinanceReceivablesNetDetailsAbstract_pn3n3_zORWmsc6OtI1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220630_zUl8t6BKq96k" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20211231_zz8W6kSgeGyh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zfQsMyDpqyNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">133,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zg25sEJbN1ci" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,220</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">53,629</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maNRNzInv_zGgX8S0jb7Dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">183,224</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,941</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNRNzInv_zSwZjrNnn2Vd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,365</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,388</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableNet_iTI_mtNRNzInv_zG3Ivh6AJJN2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">174,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	183224000	usd
CY2021Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	189941000	usd
CY2022Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8365000	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8388000	usd
CY2022Q2	us-gaap	Notes Receivable Net NotesReceivableNet	174859000	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	181553000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2790000	usd
	swkh	Disclosure Finance Receivables Net Details2 Abstract DisclosureFinanceReceivablesNetDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureFinanceReceivablesNetDetails2Abstract_pn3n3_zrvq2ut8Bs82" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zrKCOxK48MIh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zoOq6Y9fam47" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20220630_zMV9dc6ETPw9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zoVLt5haZRWf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zOfiEiJaKuue" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49F_20211231_zg6lZBCatBFl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zBPhv3dsye52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,789</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">123,215</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">133,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">118,024</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zTWfDAkIfkz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Royalty purchases, net of credit loss allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,127</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38,728</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,855</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,362</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,879</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">45,241</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesReceivableNet_iI_zjcXNjNuxoV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 17.3pt; text-indent: -8.65pt">Total carrying value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">12,916</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">161,943</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">174,859</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">21,650</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">159,903</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Notes Receivable Net NotesReceivableNet	174859000	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	181553000	usd
	swkh	Disclosure Marketable Investments Details Abstract DisclosureMarketableInvestmentsDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--DisclosureMarketableInvestmentsDetailsAbstract_pn3n3_zSub1Bc9yeQc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20220630_zV5kPWKrUt3i" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20211231_zI8cL09C5Ql8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_maIzegN_zKCzlsFPHS94" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Corporate debt securities</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">98</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">119</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketableSecurities_iI_maIzegN_zmjEqmxh5Cma" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,034</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Investments_iTI_mtIzegN_zjgnIV0uCl6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total marketable investments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">585</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	98000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	119000	usd
CY2022Q2	us-gaap	Marketable Securities MarketableSecurities	487000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	1034000	usd
CY2022Q2	us-gaap	Investments Investments	585000	usd
CY2021Q4	us-gaap	Investments Investments	1153000	usd
	swkh	Disclosure Marketable Investments Details2 Abstract DisclosureMarketableInvestmentsDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureMarketableInvestmentsDetails2Abstract_pn3n3_zB4Fp49XTVqe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross <br/>Unrealized <br/>Gains</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross <br/>Unrealized <br/>Loss</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: bold">June 30, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zTzobpnJ3Cj6" style="width: 8%; text-align: right">98</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zmLUNNvCSog7" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0602">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zgSct1kQPmZc" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecurities_iI_c20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zVTFQhZCPtTk" style="width: 8%; text-align: right">98</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zkxMwY8u4aqf" style="text-align: right">119</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zpMcNkAuT4i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> </table>
	swkh	Disclosure Marketable Investments Details3 Abstract DisclosureMarketableInvestmentsDetails3Abstract	<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureMarketableInvestmentsDetails3Abstract_pn3n3_z8jnsGTwbywg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 3)"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended <br/>June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Unrealized net (loss) gain on equity securities reflected in the unaudited condensed consolidated statements of income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220401__20220630_z6KfE5n8HpX7" style="width: 8%; text-align: right">(519</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210401__20210630_zP5oTTrGlhIg" style="width: 8%; text-align: right">283</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20220630_z2FQpO5MLBQ1" style="width: 8%; text-align: right">(547</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20210630_zhfUgac7P7d2" style="width: 8%; text-align: right">1,215</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-519000	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	283000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-547000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1215000	usd
	swkh	Disclosure Intangible Assets Details Abstract DisclosureIntangibleAssetsDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_z30vwU9WD8Z8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book<br/> Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book<br/> Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="font-size: 10pt">Licensing Agreement<sup id="xdx_F47_zbKrF59h2wB2">(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zku4b7pJ2Q8" style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zAQY3sNYzzhi" style="width: 6%; text-align: right">20,680</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsCurrent_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zQT8PUFqHDGh" style="width: 6%; text-align: right">8,720</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_ztLjrSaCyQ0g" style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zAR4CfVnqiQ5" style="width: 6%; text-align: right">19,780</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_z3OiRSv5muQ" style="width: 6%; text-align: right">9,620</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z4hMruWyoLt8" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zzmIiGpRA0C1" style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsCurrent_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeWQJOMCYzz4" style="text-align: right">150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zGnrHnn8Q0Q9" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zD8TMtA9vP74" style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zr08FPNDq3sh" style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMNkpvcj4tT4" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zs6Kvjhx9e6c" style="border-bottom: Black 1pt solid; text-align: right">68</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsCurrent_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzsUywjcYtAg" style="border-bottom: Black 1pt solid; text-align: right">172</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzxXeAaYF1n7" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoh4WTcZ4YY3" style="border-bottom: Black 1pt solid; text-align: right">56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxF6rk0NaxKj" style="border-bottom: Black 1pt solid; text-align: right">184</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630_z8DwFasGTHbg" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630_z1oDS7Gyi7we" style="border-bottom: Black 2.5pt double; text-align: right">20,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsCurrent_iI_c20220630_zTKwzhlOdtu" style="border-bottom: Black 2.5pt double; text-align: right">9,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231_z3RJ8Zi8G8z4" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zMrGwUgNzS7c" style="border-bottom: Black 2.5pt double; text-align: right">19,886</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsCurrent_iI_c20211231_zcQxJwaujGAf" style="border-bottom: Black 2.5pt double; text-align: right">9,964</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	29850000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	20808000	usd
CY2022Q2	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	9042000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	29850000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19886000	usd
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	9964000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2300000	usd
	swkh	Disclosure Intangible Assets Details2 Abstract DisclosureIntangibleAssetsDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zgQrciKV2Uih" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Fiscal Year</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220630_zcD23EaTkQmf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzQY9_zaudOnFageVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 47%; text-align: left">Remainder of 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">851</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_zo2arxxqdoQ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,703</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zSNe7JtaGYA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,546</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zM2LuaGxMChj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zsiSi64MfZDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_zsjcXFJhiq7i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,790</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zcuyWj8eKwTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	851000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1703000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1546000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1076000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1076000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9042000	usd
CY2022Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	8500000	usd
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	8500000	usd
	swkh	Disclosure Commitments And Contingencies Details Abstract DisclosureCommitmentsAndContingenciesDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureCommitmentsAndContingenciesDetailsAbstract_pn3n3_zWDjVnDKMXu4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"/><td style="padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; text-align: left"/><td id="xdx_483_eus-gaap--CommitmentsAndContingencies_iI_pn3n6_zYhZnJDfSpq4" style="border-bottom: Black 1pt solid; text-align: right"/><td style="padding-bottom: 1pt; text-align: left"/></tr> <tr id="xdx_41F_20220630__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrioHealthcareLtdLoanMember_zNe7S2madtTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">Trio Healthcare Ltd. Loan</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1.4</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_414_20220630__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember_zfQB4iVpDSih" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt">Total unfunded commitments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
	swkh	Disclosure Fair Value Measurements Details Abstract DisclosureFairValueMeasurementsDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_pn3n3_zWnijYbt85y1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUr5lpQD94Pe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total <br/>Carrying <br/>Value in <br/>Consolidated <br/>Balance <br/>Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsFD8XxWvH3d" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices <br/>in Active <br/>Markets for <br/>Identical <br/>Assets <br/>or Liabilities <br/>(Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zo7vuK8q2Jeb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant <br/>Other <br/>Observable <br/>Inputs <br/>(Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCQy9Yo6baq1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant <br/>Unobservable <br/>Inputs <br/>(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_zBMvtzivmip1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zfI2HdlbFLA2" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,481</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,481</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zwopO4QMjzx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0697">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zuisXZf1aMN2" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ContingentConsiderationPayable_i01I_pn3n3_z15F7sTx5cx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvpm99LYRz32" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total <br/>Carrying <br/>Value in <br/>Consolidated <br/>Balance <br/>Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPXrREIXEtzj" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices <br/>in Active <br/>Markets for <br/>Identical <br/>Assets <br/>or Liabilities <br/>(Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zACB1ZkNWpUb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant <br/>Other <br/>Observable <br/>Inputs <br/>(Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAPzPqtwgEY2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant <br/>Unobservable <br/>Inputs <br/>(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--FinancialAssetsAbstract_iB_ztyfzjRgyqOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--WarrantAssets_i01I_pn3n3_zQaMbk8hA5Vf" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zbDSXB78hSt1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0722">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FinancialLiabilitiesAbstract_iB_zIYtLDdoO5Lf" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ContingentConsiderationPayable_i01I_pn3n3_zm6Tyt9VUcZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0731">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0732">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>
	swkh	Disclosure Fair Value Measurements Details2 Abstract DisclosureFairValueMeasurementsDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_pn3n3_zFvHcPVktGqg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220101__20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCML3hhkYVp3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zp1aZME3wAu6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td></tr> <tr id="xdx_401_ecustom--WarrantAssets_iS_z5mgIYNmIwfi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair value - December 31, 2021</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 35%">Fair value - December 31, 2020</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,972</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--WarrantIssuances_zU7ZXLLlBRl9" style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227</td><td style="text-align: left"> </td><td> </td> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WarrantsCanceled_zWuJxWgk8JJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">—</span></td><td style="text-align: left"> </td><td> </td> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0746">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueAdjustmentOfWarrants_ziesjZ2CXQsd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">892</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantAssets_iE_zWcNc9Mvtmnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,481</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
	swkh	Disclosure Fair Value Measurements Details3 Abstract DisclosureFairValueMeasurementsDetails3Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureFairValueMeasurementsDetails3Abstract_pid_zFw8dMmUFT48" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>June 30, 2022</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Dividend rate range</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zLi2xuGKJEJ7">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z6FBbIWFdL02"><span style="-sec-ix-hidden: xdx2ixbrl0758">—</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z3MiWp3sPtmh">2.9%</span> to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z4TZWCXLTso4">3.0%</span></span></td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zA6W8UIwUch">0.97%</span> to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zIck2oHKjEY7">1.44%</span></span></td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (years) range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"> <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zTEO23Tgvvzi" title="::XDX::P2Y1M6D">2.1</span> to <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zQ3wXHgaVAOg" title="::XDX::P6Y8M12D">6.7</span> </span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zB1xhcINvQsg" title="::XDX::P2Y7M6D">2.6</span> to <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5Q2GBL7KNI1" title="::XDX::P7Y">7.0</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zJ6m60O0oQT7">52.6%</span> to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zO4XSQocGwG7">147.5%</span> </span></td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zpZILdHCPKai">60.2%</span> to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zfmb9nyZ2Wz4">142.0%</span></span></td><td style="text-align: left"/></tr> </table>
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3018000	usd
	swkh	Disclosure Fair Value Measurements Details4 Abstract DisclosureFairValueMeasurementsDetails4Abstract	<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureFairValueMeasurementsDetails4Abstract_pn3n3_zec7qosQ9sQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_z0jy2eMhRaQl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total <br/>Carrying <br/>Value in <br/>Consolidated <br/>Balance <br/>Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_z3vJZujuX0Ag" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices <br/>in Active <br/>Markets for <br/>Identical <br/>Assets <br/>or Liabilities <br/>(Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zjjBQzLarbC4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant <br/>Other <br/>Observable <br/>Inputs <br/>(Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zkP1coVmh3u2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant <br/>Unobservable <br/>Inputs <br/>(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43D_c20220630_eus-gaap--InvestmentsFairValueDisclosure_iI_zrT6cxybu6L9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: bold; text-align: justify">June 30, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,604</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,604</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20211231_eus-gaap--InvestmentsFairValueDisclosure_iI_z6LLUZG1ojod" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td></tr> </table>
	swkh	Disclosure Fair Value Measurements Details5 Abstract DisclosureFairValueMeasurementsDetails5Abstract	<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--DisclosureFairValueMeasurementsDetails5Abstract_pn3n3_z034C8KRh2lc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220630__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zM0lekgX0VB7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220630__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zVY28l7yt1g6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zUmxNd7b4ZDe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z3nQDCUhJnna" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zQVDetDTn7b1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_z8G3m6p2rmCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_z79iqqXsPdfi" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Cash and cash equivalents</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">55,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">55,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">55,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LoansReceivableFairValueDisclosure_i01I_zKCzS0kS28u2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,859</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentsFairValueDisclosure_i01I_zsAsV450fv05" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAssetsFairValueDisclosure_i01I_zh7Celw1t1v2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,481</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,481</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zrm2ofcvjRY9" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ContingentConsiderationPayable_i01I_zdfXomu6mwrb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0829">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As of December 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_z6J0BjFPX459" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zy0RQ7WBA02e" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdnym3RXLeoi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLtk1lBoPA7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk6gSoQGDc22" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zwZJSNik5dAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_zhdYXQC8D0e9" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Cash and cash equivalents</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LoansReceivableFairValueDisclosure_i01I_z8FTIp70f1A4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentsFairValueDisclosure_i01I_zzORMJxwaPt7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherAssetsFairValueDisclosure_i01I_zh4aW1veKiE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesAbstract_iB_zMEuk8gOcJOk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ContingentConsiderationPayable_i01I_zWpyAq25FKq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>
	swkh	Disclosure Revenue Recognition Details Abstract DisclosureRevenueRecognitionDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureRevenueRecognitionDetailsAbstract_pn3n3_zr2zJhmjlx5i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49B_20220401__20220630_z6K4YWSJIupf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_492_20210401__20210630_zI7JrjGzLd08" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220630_zReU6hKUnvY3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20210101__20210630_zsWnk99Orytb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended <br/>June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended <br/>June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zsnQmTzkXKN5" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">License Agreement</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">16</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,431</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">132</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,610</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zDgUx28wLbB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pharmaceutical Development and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">98</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">698</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">545</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zVnZv9N3hpz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,461</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,155</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
	us-gaap	Profit Loss ProfitLoss	17359000	usd
	swkh	Disclosure Revenue Recognition Details2 Abstract DisclosureRevenueRecognitionDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureRevenueRecognitionDetails2Abstract_pn3n3_ztQbOQRi3JP4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220630_zsJNbgy1TMR7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20211231_znLnvNfAxxv8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zepQvTOQOOf2" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: left">Deferred revenue</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">56</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">185</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_zPF988AQ7676" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	56000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	185000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	56000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	185000	usd
	swkh	Disclosure Segment Information Details Abstract DisclosureSegmentInformationDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--DisclosureSegmentInformationDetailsAbstract_pn3n3_znMKlj1ymBhj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20220401__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zgeWBHQ1Hmpc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220401__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zcRfEWapsrlg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49E_20220401__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zyX439r17RNc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20220401__20220630_zMoYzcKX1NPc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance<br/> Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical<br/> Development and<br/> Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company<br/> and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--RevenuesExcludingOtherRevenue_z6LVDzVHwoN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">6,828</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">114</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">6,942</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpense_zQ25jg7NMCJi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0918">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0919">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_zhvhSm5VGlsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DepreciationAndAmortization_z02pt3DLLd9b" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0927">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_zoSKZ7yqjm12" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">905</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherOperatingIncomeExpenseNet_zgKAbO3zuluc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(991</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(991</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zTwxpKePK2Zj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_z3Uc1QRSbaDk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,755</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,896</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,294</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_491_20210401__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zSRejWj5wOv9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20210401__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_z3ghVkALpUE" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20210401__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zfuBjCq4DvAb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_491_20210401__20210630_zerNLTWvhYbe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance<br/> Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical<br/> Development and<br/> Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company<br/> and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_ecustom--RevenuesExcludingOtherRevenue_z4kaPBHMj5k5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">11,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0954">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">22,266</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_zHIMGzXplYKg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zPUHVcTh9TGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_zHfGqLYALsI7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0967">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">811</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_zJ8CfPDOkiP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0972">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0974">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_zpSxgZLOscMj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,360</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherOperatingIncomeExpenseNet_zFFin8ZesfYd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_z90LGTPRTUFh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,528</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,528</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ProfitLoss_zbnGKRyTfNjb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,957</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,970</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zzp24AurvyX5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_491_20220101__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zNK08fggXOlh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20220101__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zc2KqUlGPzF" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220101__20220630_zVnk1nZoFsH2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance<br/> Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical<br/> Development and<br/> Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company<br/> and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--RevenuesExcludingOtherRevenue_zRGK4yIqO9Pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">17,243</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">350</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">17,593</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueNotFromContractWithCustomerOther_za0yCm2KAZX3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InterestExpense_zupY7IzbTVMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zOCelOPQQw4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,381</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_zBoFSNEJhKZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,329</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,330</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_zAKBIXJDEgS9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,940</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,178</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherOperatingIncomeExpenseNet_zbh5dd2zngC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,712</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1029">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,712</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_zzFIS0KudSh7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,269</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ProfitLoss_zODAH4St8hXe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,820</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,404</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,043</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20210101__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zQWgtdFzy9b7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49B_20210101__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zphZmYIyi5j7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49B_20210101__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zsXC7Bf8HgO3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20210101__20210630_zz5SOeyoxr7b" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance<br/> Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical <br/> Development and<br/> Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company<br/> and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_ecustom--RevenuesExcludingOtherRevenue_zIx3RMBdmG8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,484</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,659</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">31,143</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueNotFromContractWithCustomerOther_z4RlIcbCgDqi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestExpense_zEA3GbSHgWzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_zVw7Mk13lAtg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1059">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationAndAmortization_zqsa6dVNmGEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,493</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_zrNo64joulid" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_zrmSCkVVwyM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,245</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherOperatingIncomeExpenseNet_zSJP3Lndlold" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,107</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_zVKMA4WMvNpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,467</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_zm2TANlzNdEa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,634</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,493</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,359</td><td style="text-align: left"> </td></tr> </table>
CY2022Q2	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	6942000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	80000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1480000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	626000	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-991000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	182000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	565000	usd
CY2021Q2	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	22266000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	94000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1542000	usd
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	811000	usd
CY2021Q2	swkh	Change In Fair Value Of Acquisitionrelated Contingent Consideration ChangeInFairValueOfAcquisitionrelatedContingentConsideration	-147000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3360000	usd
CY2021Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	892000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3528000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	13970000	usd
	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	17593000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	480000	usd
	us-gaap	Interest Expense InterestExpense	160000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3381000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1330000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6178000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1712000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1269000	usd
	us-gaap	Profit Loss ProfitLoss	4043000	usd
	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	31143000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	496000	usd
	us-gaap	Interest Expense InterestExpense	239000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3090000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2493000	usd
	swkh	Change In Fair Value Of Acquisitionrelated Contingent Consideration ChangeInFairValueOfAcquisitionrelatedContingentConsideration	-147000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6245000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2107000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4467000	usd

dei

Entity Central Index Key

EntityCentralIndexKey

0001089907

dei

Amendment Flag

AmendmentFlag

false

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2022

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q2

CY2022Q2

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

usd

CY2021Q1

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

usd

CY2021Q2

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

usd

swkh

Change In Fair Value Of Acquisitionrelated Contingent Consideration

ChangeInFairValueOfAcquisitionrelatedContingentConsideration

usd

us-gaap

Payment For Contingent Consideration Liability Financing Activities

PaymentForContingentConsiderationLiabilityFinancingActivities

usd

dei

Document Type

DocumentType

10-Q

dei

Document Quarterly Report

DocumentQuarterlyReport

true

dei

Document Period End Date

DocumentPeriodEndDate

2022-06-30

CY2021Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9964000

usd

dei

Document Transition Report

DocumentTransitionReport

false

dei

Entity File Number

EntityFileNumber

001-39184

dei

Entity Registrant Name

EntityRegistrantName

SWK Holdings Corporation

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

DE

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

77-0435679

dei

Entity Address Address Line1

EntityAddressAddressLine1

14755 Preston Road

dei

Entity Address Address Line2

EntityAddressAddressLine2

Suite 105

dei

Entity Address City Or Town

EntityAddressCityOrTown

Dallas

dei

Entity Address State Or Province

EntityAddressStateOrProvince

TX

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

75254

dei

City Area Code

CityAreaCode

(972)

dei

Local Phone Number

LocalPhoneNumber

687-7250

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

dei

Entity Filer Category

EntityFilerCategory

Non-accelerated Filer

dei

Entity Small Business

EntitySmallBusiness

true

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

dei

Entity Shell Company

EntityShellCompany

false

CY2022Q3

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

12828704

shares

CY2022Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

55118000

usd

CY2021Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

42863000

usd

CY2022Q2

us-gaap

Accounts Receivable Net

AccountsReceivableNet

1869000

usd

CY2021Q4

us-gaap

Accounts Receivable Net

AccountsReceivableNet

1803000

usd

CY2022Q2

us-gaap

Marketable Securities

MarketableSecurities

487000

usd

CY2021Q4

us-gaap

Marketable Securities

MarketableSecurities

1034000

usd

CY2022Q2

us-gaap

Other Assets Current

OtherAssetsCurrent

1366000

usd

CY2021Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

1727000

usd

CY2022Q2

us-gaap

Assets Current

AssetsCurrent

58840000

usd

CY2021Q4

us-gaap

Assets Current

AssetsCurrent

47427000

usd

CY2022Q2

us-gaap

Notes And Loans Receivable Net Current

NotesAndLoansReceivableNetCurrent

174859000

usd

CY2021Q4

us-gaap

Notes And Loans Receivable Net Current

NotesAndLoansReceivableNetCurrent

181553000

usd

CY2022Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

98000

usd

CY2021Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

119000

usd

CY2022Q2

us-gaap

Cost Method Investments

CostMethodInvestments

3491000

usd

CY2021Q4

us-gaap

Cost Method Investments

CostMethodInvestments

3491000

usd

CY2022Q2

us-gaap

Deferred Income Tax Assets Net

DeferredIncomeTaxAssetsNet

19281000

usd

CY2021Q4

us-gaap

Deferred Income Tax Assets Net

DeferredIncomeTaxAssetsNet

20539000

usd

CY2022Q2

swkh

Warrant Assets

WarrantAssets

2481000

usd

CY2021Q4

swkh

Warrant Assets

WarrantAssets

3419000

usd

CY2022Q2

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9042000

usd

CY2022Q2

us-gaap

Goodwill

8404000

usd

CY2021Q4

us-gaap

Goodwill

8404000

usd

CY2022Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

6071000

usd

CY2021Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

5779000

usd

CY2022Q2

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1858000

usd

CY2021Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1970000

usd

CY2022Q2

us-gaap

Assets

284425000

usd

CY2021Q4

us-gaap

Assets

282665000

usd

CY2022Q2

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

2776000

usd

CY2021Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

5087000

usd

CY2021Q4

us-gaap

Lines Of Credit Current

LinesOfCreditCurrent

8000

usd

CY2022Q2

us-gaap

Liabilities Current

LiabilitiesCurrent

2776000

usd

CY2021Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

5095000

usd

CY2022Q2

swkh

Contingent Consideration Payable

ContingentConsiderationPayable

8530000

usd

CY2021Q4

swkh

Contingent Consideration Payable

ContingentConsiderationPayable

8530000

usd

CY2022Q2

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1589000

usd

CY2021Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1804000

usd

CY2022Q2

us-gaap

Liabilities

12895000

usd

CY2021Q4

us-gaap

Liabilities

15429000

usd

CY2022Q2

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2021Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2022Q2

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

shares

CY2021Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

shares

CY2022Q2

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2022Q2

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2021Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2021Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2022Q2

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2021Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2022Q2

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

250000000

shares

CY2021Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

250000000

shares

CY2022Q2

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

12839118

shares

CY2022Q2

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

12839118

shares

CY2021Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

12836133

shares

CY2021Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

12836133

shares

CY2022Q2

us-gaap

Common Stock Value

CommonStockValue

13000

usd

CY2021Q4

us-gaap

Common Stock Value

CommonStockValue

13000

usd

CY2022Q2

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

4431970000

usd

CY2021Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

4431719000

usd

CY2022Q2

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-4160453000

usd

CY2021Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-4164496000

usd

CY2022Q2

us-gaap

Stockholders Equity

StockholdersEquity

271530000

usd

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

267236000

usd

CY2022Q2

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

284425000

usd

CY2021Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

282665000

usd

CY2022Q2

us-gaap

Interest And Fee Income Loans And Leases

InterestAndFeeIncomeLoansAndLeases

6828000

usd

CY2021Q2

us-gaap

Interest And Fee Income Loans And Leases

InterestAndFeeIncomeLoansAndLeases

11805000

usd

us-gaap

Interest And Fee Income Loans And Leases

InterestAndFeeIncomeLoansAndLeases

17243000

usd

us-gaap

Interest And Fee Income Loans And Leases

InterestAndFeeIncomeLoansAndLeases

20484000

usd

CY2022Q2

swkh

Pharmaceutical Development Revenue

PharmaceuticalDevelopmentRevenue

114000

usd

us-gaap

Amortization Of Deferred Loan Origination Fees Net

AmortizationOfDeferredLoanOriginationFeesNet

780000

usd

us-gaap

Amortization Of Deferred Loan Origination Fees Net

AmortizationOfDeferredLoanOriginationFeesNet

1130000

usd

CY2021Q2

swkh

Pharmaceutical Development Revenue

PharmaceuticalDevelopmentRevenue

10461000

usd

swkh

Pharmaceutical Development Revenue

PharmaceuticalDevelopmentRevenue

350000

usd

swkh

Pharmaceutical Development Revenue

PharmaceuticalDevelopmentRevenue

10659000

usd

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

480000

usd

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

496000

usd

CY2022Q2

us-gaap

Revenues

6942000

usd

CY2021Q2

us-gaap

Revenues

22266000

usd

us-gaap

Revenues

18073000

usd

us-gaap

Revenues

31639000

usd

CY2022Q2

us-gaap

Interest Expense

InterestExpense

80000

usd

CY2021Q2

us-gaap

Interest Expense

InterestExpense

94000

usd

us-gaap

Interest Expense

InterestExpense

160000

usd

us-gaap

Interest Expense

InterestExpense

239000

usd

CY2022Q2

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1480000

usd

CY2021Q2

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1542000

usd

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

3381000

usd

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

3090000

usd

CY2021Q2

swkh

Change In Fair Value Of Acquisitionrelated Contingent Consideration

ChangeInFairValueOfAcquisitionrelatedContingentConsideration

-147000

usd

swkh

Change In Fair Value Of Acquisitionrelated Contingent Consideration

ChangeInFairValueOfAcquisitionrelatedContingentConsideration

-147000

usd

CY2022Q2

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

626000

usd

CY2021Q2

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

811000

usd

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

1330000

usd

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

2493000

usd

CY2022Q2

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

3018000

usd

CY2021Q2

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

3360000

usd

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

6178000

usd

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

6245000

usd

CY2022Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

1738000

usd

CY2021Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

16606000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

7024000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

19719000

usd

CY2022Q2

us-gaap

Unrealized Gain Loss On Derivatives

UnrealizedGainLossOnDerivatives

-472000

usd

CY2021Q2

us-gaap

Unrealized Gain Loss On Derivatives

UnrealizedGainLossOnDerivatives

609000

usd

us-gaap

Unrealized Gain Loss On Derivatives

UnrealizedGainLossOnDerivatives

-1165000

usd

us-gaap

Unrealized Gain Loss On Derivatives

UnrealizedGainLossOnDerivatives

892000

usd

CY2022Q2

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

-519000

usd

CY2021Q2

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

283000

usd

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

-547000

usd

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

1215000

usd

CY2022Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

747000

usd

CY2021Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

17498000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

5312000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

21826000

usd

CY2022Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

182000

usd

CY2021Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

3528000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1269000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

4467000

usd

CY2022Q2

us-gaap

Profit Loss

ProfitLoss

565000

usd

CY2021Q2

us-gaap

Profit Loss

ProfitLoss

13970000

usd

us-gaap

Profit Loss

ProfitLoss

4043000

usd

us-gaap

Profit Loss

ProfitLoss

17359000

usd

CY2022Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.04

CY2021Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

1.09

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.32

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

1.36

CY2022Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.04

CY2021Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

1.09

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.31

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

1.35

CY2022Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12835000

shares

CY2021Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12796000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12833000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12794000

shares

CY2022Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12885000

shares

CY2021Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12834000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12882000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12822000

shares

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

267236000

usd

CY2022Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

85000

usd

CY2022Q1

us-gaap

Net Income Loss

NetIncomeLoss

3478000

usd

CY2022Q1

us-gaap

Stockholders Equity

StockholdersEquity

270799000

usd

CY2022Q2

us-gaap

Share Based Compensation

ShareBasedCompensation

166000

usd

CY2022Q2

us-gaap

Net Income Loss

NetIncomeLoss

565000

usd

CY2022Q2

us-gaap

Stockholders Equity

StockholdersEquity

271530000

usd

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

240512000

usd

CY2021Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

177000

usd

CY2021Q1

us-gaap

Net Income Loss

NetIncomeLoss

3389000

usd

CY2021Q1

us-gaap

Stockholders Equity

StockholdersEquity

244078000

usd

CY2021Q2

us-gaap

Share Based Compensation

ShareBasedCompensation

187000

usd

CY2021Q2

us-gaap

Net Income Loss

NetIncomeLoss

13970000

usd

CY2021Q2

us-gaap

Stockholders Equity

StockholdersEquity

258235000

usd

us-gaap

Profit Loss

ProfitLoss

4043000

usd

us-gaap

Profit Loss

ProfitLoss

17359000

usd

us-gaap

Amortization Of Financing Costs

AmortizationOfFinancingCosts

29000

usd

us-gaap

Amortization Of Financing Costs

AmortizationOfFinancingCosts

93000

usd

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

1257000

usd

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

4369000

usd

us-gaap

Fair Value Adjustment Of Warrants

FairValueAdjustmentOfWarrants

1165000

usd

us-gaap

Fair Value Adjustment Of Warrants

FairValueAdjustmentOfWarrants

-892000

usd

us-gaap

Increase Decrease In Equity Securities Fv Ni

IncreaseDecreaseInEquitySecuritiesFvNi

-547000

usd

us-gaap

Increase Decrease In Equity Securities Fv Ni

IncreaseDecreaseInEquitySecuritiesFvNi

1215000

usd

swkh

Change In Fair Value Of Acquisitionrelated Contingent Consideration

ChangeInFairValueOfAcquisitionrelatedContingentConsideration

-147000

usd

swkh

Proceeds Repayment Of Finance Receivables

ProceedsRepaymentOfFinanceReceivables

22779000

usd

us-gaap

Paid In Kind Interest

PaidInKindInterest

1599000

usd

us-gaap

Paid In Kind Interest

PaidInKindInterest

26000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

251000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

364000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

1330000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

2493000

usd

us-gaap

Increase Decrease In Interest And Dividends Receivable

IncreaseDecreaseInInterestAndDividendsReceivable

-66000

usd

us-gaap

Increase Decrease In Interest And Dividends Receivable

IncreaseDecreaseInInterestAndDividendsReceivable

-728000

usd

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

256000

usd

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

477000

usd

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-2526000

usd

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-813000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

3395000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

19250000

usd

us-gaap

Payments To Acquire Finance Receivables

PaymentsToAcquireFinanceReceivables

25350000

usd

us-gaap

Payments To Acquire Finance Receivables

PaymentsToAcquireFinanceReceivables

20100000

usd

swkh

Proceeds Repayment Of Finance Receivables

ProceedsRepaymentOfFinanceReceivables

34195000

usd

swkh

Marketable Investment Principal Payment

MarketableInvestmentPrincipalPayment

21000

usd

swkh

Marketable Investment Principal Payment

MarketableInvestmentPrincipalPayment

31000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

111000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

671000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-113000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-163000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

8868000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

2202000

usd

us-gaap

Proceeds From Repayments Of Lines Of Credit

ProceedsFromRepaymentsOfLinesOfCredit

-8000

usd

us-gaap

Proceeds From Repayments Of Lines Of Credit

ProceedsFromRepaymentsOfLinesOfCredit

-11758000

usd

us-gaap

Payment For Contingent Consideration Liability Financing Activities

PaymentForContingentConsiderationLiabilityFinancingActivities

6083000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-8000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-17841000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

12255000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

3611000

usd

CY2021Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

42863000

usd

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3008000

usd

CY2022Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

55118000

usd

CY2021Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6619000

usd

us-gaap

Use Of Estimates

UseOfEstimates

Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of accounts receivable; impairment of finance receivables; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

us-gaap

Number Of Operating Segments

NumberOfOperatingSegments

2

number

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

49000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

28000

shares

CY2022Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12885000

shares

swkh

Disclosure Net Income Per Share Details Abstract

DisclosureNetIncomePerShareDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureNetIncomePerShareDetailsAbstract_pn3n3_zFlJ2YKt4ruc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20220401__20220630_zQ07JkLEMJt2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_494_20210401__20210630_zg7Q6WDAJIhg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20220101__20220630_zKoJ8PsfvHPk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20210101__20210630_zfeTrcmOsUE5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ProfitLoss_zQTbY0jcJ378" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 8.65pt">Net income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">565</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">13,970</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,043</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">17,359</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pin3_zlODqXjnc8fi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,794</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pin3_zT1ak19fL6X3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Effect of dilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pin3_zUEhB3MTHHJe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt">Weighted-average diluted shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,885</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,882</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_zSn0yeHa6jT3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_pid_zIeYSBByOFo1" style="vertical-align: bottom; background-color: White"> <td>Diluted net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Profit Loss

ProfitLoss

565000

usd

CY2021Q2

us-gaap

Profit Loss

ProfitLoss

13970000

usd

us-gaap

Profit Loss

ProfitLoss

4043000

usd

us-gaap

Profit Loss

ProfitLoss

17359000

usd

CY2022Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12835000

shares

CY2021Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12796000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12833000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12794000

shares

CY2022Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

50000

shares

CY2021Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

38000

shares

CY2021Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12834000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12882000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12822000

shares

CY2022Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.04

CY2021Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

1.09

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.32

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

1.36

CY2022Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.04

CY2021Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

1.09

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.31

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

1.35

CY2022Q2

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

308000

shares

CY2021Q2

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

391000

shares

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

309000

shares

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

401000

shares

swkh

Disclosure Finance Receivables Net Details Abstract

DisclosureFinanceReceivablesNetDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureFinanceReceivablesNetDetailsAbstract_pn3n3_zORWmsc6OtI1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220630_zUl8t6BKq96k" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20211231_zz8W6kSgeGyh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zfQsMyDpqyNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">133,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zg25sEJbN1ci" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,220</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">53,629</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maNRNzInv_zGgX8S0jb7Dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">183,224</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,941</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNRNzInv_zSwZjrNnn2Vd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,365</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,388</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableNet_iTI_mtNRNzInv_zG3Ivh6AJJN2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">174,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Notes Receivable Gross

NotesReceivableGross

183224000

usd

CY2021Q4

us-gaap

Notes Receivable Gross

NotesReceivableGross

189941000

usd

CY2022Q2

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

8365000

usd

CY2021Q4

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

8388000

usd

CY2022Q2

us-gaap

Notes Receivable Net

NotesReceivableNet

174859000

usd

CY2021Q4

us-gaap

Notes Receivable Net

NotesReceivableNet

181553000

usd

CY2022Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense After Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

2790000

usd

swkh

Disclosure Finance Receivables Net Details2 Abstract

DisclosureFinanceReceivablesNetDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureFinanceReceivablesNetDetails2Abstract_pn3n3_zrvq2ut8Bs82" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zrKCOxK48MIh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zoOq6Y9fam47" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20220630_zMV9dc6ETPw9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zoVLt5haZRWf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20211231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zOfiEiJaKuue" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49F_20211231_zg6lZBCatBFl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zBPhv3dsye52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,789</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">123,215</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">133,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">118,024</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">136,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zTWfDAkIfkz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Royalty purchases, net of credit loss allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,127</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38,728</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,855</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,362</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,879</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">45,241</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesReceivableNet_iI_zjcXNjNuxoV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 17.3pt; text-indent: -8.65pt">Total carrying value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">12,916</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">161,943</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">174,859</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">21,650</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">159,903</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,553</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Notes Receivable Net

NotesReceivableNet

174859000

usd

CY2021Q4

us-gaap

Notes Receivable Net

NotesReceivableNet

181553000

usd

swkh

Disclosure Marketable Investments Details Abstract

DisclosureMarketableInvestmentsDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--DisclosureMarketableInvestmentsDetailsAbstract_pn3n3_zSub1Bc9yeQc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20220630_zV5kPWKrUt3i" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20211231_zI8cL09C5Ql8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_maIzegN_zKCzlsFPHS94" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Corporate debt securities</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">98</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">119</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketableSecurities_iI_maIzegN_zmjEqmxh5Cma" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,034</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Investments_iTI_mtIzegN_zjgnIV0uCl6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total marketable investments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">585</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

98000

usd

CY2021Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

119000

usd

CY2022Q2

us-gaap

Marketable Securities

MarketableSecurities

487000

usd

CY2021Q4

us-gaap

Marketable Securities

MarketableSecurities

1034000

usd

CY2022Q2

us-gaap

Investments

585000

usd

CY2021Q4

us-gaap

Investments

1153000

usd

swkh

Disclosure Marketable Investments Details2 Abstract

DisclosureMarketableInvestmentsDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureMarketableInvestmentsDetails2Abstract_pn3n3_zB4Fp49XTVqe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amortized Cost</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Unrealized Loss</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: bold">June 30, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zTzobpnJ3Cj6" style="width: 8%; text-align: right">98</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zmLUNNvCSog7" style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20220101__20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zgSct1kQPmZc" style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecurities_iI_c20220630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zVTFQhZCPtTk" style="width: 8%; text-align: right">98</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zkxMwY8u4aqf" style="text-align: right">119</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesGrossUnrealizedGains_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zpMcNkAuT4i" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> </table>

swkh

Disclosure Marketable Investments Details3 Abstract

DisclosureMarketableInvestmentsDetails3Abstract

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureMarketableInvestmentsDetails3Abstract_pn3n3_z8jnsGTwbywg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Marketable Investments (Details 3)"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Unrealized net (loss) gain on equity securities reflected in the unaudited condensed consolidated statements of income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220401__20220630_z6KfE5n8HpX7" style="width: 8%; text-align: right">(519</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210401__20210630_zP5oTTrGlhIg" style="width: 8%; text-align: right">283</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20220630_z2FQpO5MLBQ1" style="width: 8%; text-align: right">(547</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20210101__20210630_zhfUgac7P7d2" style="width: 8%; text-align: right">1,215</td><td style="width: 1%; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

-519000

usd

CY2021Q2

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

283000

usd

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

-547000

usd

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

1215000

usd

swkh

Disclosure Intangible Assets Details Abstract

DisclosureIntangibleAssetsDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_z30vwU9WD8Z8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Licensing Agreement(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zku4b7pJ2Q8" style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zAQY3sNYzzhi" style="width: 6%; text-align: right">20,680</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsCurrent_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zQT8PUFqHDGh" style="width: 6%; text-align: right">8,720</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_ztLjrSaCyQ0g" style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zAR4CfVnqiQ5" style="width: 6%; text-align: right">19,780</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_z3OiRSv5muQ" style="width: 6%; text-align: right">9,620</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z4hMruWyoLt8" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zzmIiGpRA0C1" style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsCurrent_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeWQJOMCYzz4" style="text-align: right">150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zGnrHnn8Q0Q9" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zD8TMtA9vP74" style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zr08FPNDq3sh" style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMNkpvcj4tT4" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zs6Kvjhx9e6c" style="border-bottom: Black 1pt solid; text-align: right">68</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsCurrent_iI_c20220630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzsUywjcYtAg" style="border-bottom: Black 1pt solid; text-align: right">172</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzxXeAaYF1n7" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoh4WTcZ4YY3" style="border-bottom: Black 1pt solid; text-align: right">56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20211231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxF6rk0NaxKj" style="border-bottom: Black 1pt solid; text-align: right">184</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20220630_z8DwFasGTHbg" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220630_z1oDS7Gyi7we" style="border-bottom: Black 2.5pt double; text-align: right">20,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsCurrent_iI_c20220630_zTKwzhlOdtu" style="border-bottom: Black 2.5pt double; text-align: right">9,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20211231_z3RJ8Zi8G8z4" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zMrGwUgNzS7c" style="border-bottom: Black 2.5pt double; text-align: right">19,886</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsCurrent_iI_c20211231_zcQxJwaujGAf" style="border-bottom: Black 2.5pt double; text-align: right">9,964</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

29850000

usd

CY2022Q2

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

20808000

usd

CY2022Q2

us-gaap

Intangible Assets Current

IntangibleAssetsCurrent

9042000

usd

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

29850000

usd

CY2021Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

19886000

usd

CY2021Q4

us-gaap

Intangible Assets Current

IntangibleAssetsCurrent

9964000

usd

CY2022Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

400000

usd

CY2021Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

700000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

900000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

2300000

usd

swkh

Disclosure Intangible Assets Details2 Abstract

DisclosureIntangibleAssetsDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zgQrciKV2Uih" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Fiscal Year</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220630_zcD23EaTkQmf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzQY9_zaudOnFageVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 47%; text-align: left">Remainder of 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">851</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_zo2arxxqdoQ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,703</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zSNe7JtaGYA9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,546</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zM2LuaGxMChj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zsiSi64MfZDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_zsjcXFJhiq7i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,790</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zcuyWj8eKwTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

851000

usd

CY2022Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

1703000

usd

CY2022Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

1546000

usd

CY2022Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

1076000

usd

CY2022Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

1076000

usd

CY2022Q2

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

9042000

usd

CY2022Q2

us-gaap

Contingent Consideration Classified As Equity Fair Value Disclosure

ContingentConsiderationClassifiedAsEquityFairValueDisclosure

8500000

usd

CY2021Q4

us-gaap

Contingent Consideration Classified As Equity Fair Value Disclosure

ContingentConsiderationClassifiedAsEquityFairValueDisclosure

8500000

usd

swkh

Disclosure Commitments And Contingencies Details Abstract

DisclosureCommitmentsAndContingenciesDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureCommitmentsAndContingenciesDetailsAbstract_pn3n3_zWDjVnDKMXu4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"/><td style="padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; text-align: left"/><td id="xdx_483_eus-gaap--CommitmentsAndContingencies_iI_pn3n6_zYhZnJDfSpq4" style="border-bottom: Black 1pt solid; text-align: right"/><td style="padding-bottom: 1pt; text-align: left"/></tr> <tr id="xdx_41F_20220630__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrioHealthcareLtdLoanMember_zNe7S2madtTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">Trio Healthcare Ltd. Loan</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1.4</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_414_20220630__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember_zfQB4iVpDSih" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt">Total unfunded commitments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

swkh

Disclosure Fair Value Measurements Details Abstract

DisclosureFairValueMeasurementsDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_pn3n3_zWnijYbt85y1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUr5lpQD94Pe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total Carrying Value in Consolidated Balance Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsFD8XxWvH3d" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zo7vuK8q2Jeb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other Observable Inputs (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCQy9Yo6baq1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_zBMvtzivmip1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zfI2HdlbFLA2" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,481</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,481</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zwopO4QMjzx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zuisXZf1aMN2" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ContingentConsiderationPayable_i01I_pn3n3_z15F7sTx5cx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 (in thousands): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvpm99LYRz32" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total Carrying Value in Consolidated Balance Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPXrREIXEtzj" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zACB1ZkNWpUb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other Observable Inputs (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAPzPqtwgEY2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--FinancialAssetsAbstract_iB_ztyfzjRgyqOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--WarrantAssets_i01I_pn3n3_zQaMbk8hA5Vf" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zbDSXB78hSt1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FinancialLiabilitiesAbstract_iB_zIYtLDdoO5Lf" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ContingentConsiderationPayable_i01I_pn3n3_zm6Tyt9VUcZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>

swkh

Disclosure Fair Value Measurements Details2 Abstract

DisclosureFairValueMeasurementsDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_pn3n3_zFvHcPVktGqg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220101__20220630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCML3hhkYVp3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zp1aZME3wAu6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td></tr> <tr id="xdx_401_ecustom--WarrantAssets_iS_z5mgIYNmIwfi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair value - December 31, 2021</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 35%">Fair value - December 31, 2020</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,972</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--WarrantIssuances_zU7ZXLLlBRl9" style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227</td><td style="text-align: left"> </td><td> </td> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WarrantsCanceled_zWuJxWgk8JJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueAdjustmentOfWarrants_ziesjZ2CXQsd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">892</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantAssets_iE_zWcNc9Mvtmnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,481</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

swkh

Disclosure Fair Value Measurements Details3 Abstract

DisclosureFairValueMeasurementsDetails3Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureFairValueMeasurementsDetails3Abstract_pid_zFw8dMmUFT48" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Dividend rate range</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zLi2xuGKJEJ7">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z6FBbIWFdL02">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z3MiWp3sPtmh">2.9% to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z4TZWCXLTso4">3.0%</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zA6W8UIwUch">0.97% to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zIck2oHKjEY7">1.44%</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (years) range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zTEO23Tgvvzi" title="::XDX::P2Y1M6D">2.1 to <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zQ3wXHgaVAOg" title="::XDX::P6Y8M12D">6.7 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zB1xhcINvQsg" title="::XDX::P2Y7M6D">2.6 to <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5Q2GBL7KNI1" title="::XDX::P7Y">7.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zJ6m60O0oQT7">52.6% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zO4XSQocGwG7">147.5% </td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zpZILdHCPKai">60.2% to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zfmb9nyZ2Wz4">142.0%</td><td style="text-align: left"/></tr> </table>

CY2022Q2

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

3018000

usd

swkh

Disclosure Fair Value Measurements Details4 Abstract

DisclosureFairValueMeasurementsDetails4Abstract

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureFairValueMeasurementsDetails4Abstract_pn3n3_zec7qosQ9sQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_z0jy2eMhRaQl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total Carrying Value in Consolidated Balance Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_z3vJZujuX0Ag" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zjjBQzLarbC4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other Observable Inputs (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zkP1coVmh3u2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43D_c20220630_eus-gaap--InvestmentsFairValueDisclosure_iI_zrT6cxybu6L9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: bold; text-align: justify">June 30, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,604</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,604</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20211231_eus-gaap--InvestmentsFairValueDisclosure_iI_z6LLUZG1ojod" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,612</td><td style="text-align: left"> </td></tr> </table>

swkh

Disclosure Fair Value Measurements Details5 Abstract

DisclosureFairValueMeasurementsDetails5Abstract

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--DisclosureFairValueMeasurementsDetails5Abstract_pn3n3_z034C8KRh2lc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220630__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zM0lekgX0VB7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220630__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zVY28l7yt1g6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zUmxNd7b4ZDe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z3nQDCUhJnna" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zQVDetDTn7b1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_z8G3m6p2rmCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_z79iqqXsPdfi" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Cash and cash equivalents</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">55,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">55,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">55,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LoansReceivableFairValueDisclosure_i01I_zKCzS0kS28u2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,859</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentsFairValueDisclosure_i01I_zsAsV450fv05" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAssetsFairValueDisclosure_i01I_zh7Celw1t1v2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,481</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,481</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zrm2ofcvjRY9" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ContingentConsiderationPayable_i01I_zdfXomu6mwrb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table> As of December 31, 2021 (in thousands): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_z6J0BjFPX459" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20211231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_zy0RQ7WBA02e" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdnym3RXLeoi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrLtk1lBoPA7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk6gSoQGDc22" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zwZJSNik5dAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_zhdYXQC8D0e9" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Cash and cash equivalents</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">42,863</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LoansReceivableFairValueDisclosure_i01I_z8FTIp70f1A4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,553</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentsFairValueDisclosure_i01I_zzORMJxwaPt7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherAssetsFairValueDisclosure_i01I_zh4aW1veKiE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesAbstract_iB_zMEuk8gOcJOk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ContingentConsiderationPayable_i01I_zWpyAq25FKq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,530</td><td style="text-align: left"> </td></tr> </table>

swkh

Disclosure Revenue Recognition Details Abstract

DisclosureRevenueRecognitionDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureRevenueRecognitionDetailsAbstract_pn3n3_zr2zJhmjlx5i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49B_20220401__20220630_z6K4YWSJIupf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_492_20210401__20210630_zI7JrjGzLd08" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220630_zReU6hKUnvY3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20210101__20210630_zsWnk99Orytb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zsnQmTzkXKN5" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">License Agreement</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">16</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,431</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">132</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,610</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zDgUx28wLbB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pharmaceutical Development and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">98</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">698</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">545</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zVnZv9N3hpz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 8.65pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,461</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,155</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

us-gaap

Profit Loss

ProfitLoss

17359000

usd

swkh

Disclosure Revenue Recognition Details2 Abstract

DisclosureRevenueRecognitionDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureRevenueRecognitionDetails2Abstract_pn3n3_ztQbOQRi3JP4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220630_zsJNbgy1TMR7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20211231_znLnvNfAxxv8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zepQvTOQOOf2" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: left">Deferred revenue</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">56</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">185</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_zPF988AQ7676" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 8.65pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2022Q2

us-gaap

Deferred Revenue

DeferredRevenue

56000

usd

CY2021Q4

us-gaap

Deferred Revenue

DeferredRevenue

185000

usd

CY2022Q2

us-gaap

Contract With Customer Liability

ContractWithCustomerLiability

56000

usd

CY2021Q4

us-gaap

Contract With Customer Liability

ContractWithCustomerLiability

185000

usd

swkh

Disclosure Segment Information Details Abstract

DisclosureSegmentInformationDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--DisclosureSegmentInformationDetailsAbstract_pn3n3_znMKlj1ymBhj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20220401__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zgeWBHQ1Hmpc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220401__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zcRfEWapsrlg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49E_20220401__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zyX439r17RNc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20220401__20220630_zMoYzcKX1NPc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--RevenuesExcludingOtherRevenue_z6LVDzVHwoN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">6,828</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">114</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">6,942</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpense_zQ25jg7NMCJi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_zhvhSm5VGlsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DepreciationAndAmortization_z02pt3DLLd9b" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_zoSKZ7yqjm12" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">905</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherOperatingIncomeExpenseNet_zgKAbO3zuluc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(991</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(991</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zTwxpKePK2Zj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_z3Uc1QRSbaDk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,755</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,896</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,294</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_491_20210401__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zSRejWj5wOv9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20210401__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_z3ghVkALpUE" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_499_20210401__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zfuBjCq4DvAb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_491_20210401__20210630_zerNLTWvhYbe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_ecustom--RevenuesExcludingOtherRevenue_z4kaPBHMj5k5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">11,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">22,266</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_zHIMGzXplYKg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zPUHVcTh9TGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_zHfGqLYALsI7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">811</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_zJ8CfPDOkiP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_zpSxgZLOscMj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,360</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherOperatingIncomeExpenseNet_zFFin8ZesfYd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_z90LGTPRTUFh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,528</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,528</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ProfitLoss_zbnGKRyTfNjb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,957</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,970</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zzp24AurvyX5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_491_20220101__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zNK08fggXOlh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20220101__20220630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zc2KqUlGPzF" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20220101__20220630_zVnk1nZoFsH2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--RevenuesExcludingOtherRevenue_zRGK4yIqO9Pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">17,243</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">350</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">17,593</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueNotFromContractWithCustomerOther_za0yCm2KAZX3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InterestExpense_zupY7IzbTVMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zOCelOPQQw4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,381</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_zBoFSNEJhKZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,329</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,330</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_zAKBIXJDEgS9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,940</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,178</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherOperatingIncomeExpenseNet_zbh5dd2zngC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,712</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,712</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_zzFIS0KudSh7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,269</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ProfitLoss_zODAH4St8hXe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,820</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,404</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,043</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20210101__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zQWgtdFzy9b7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49B_20210101__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zphZmYIyi5j7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49B_20210101__20210630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zsXC7Bf8HgO3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49D_20210101__20210630_zz5SOeyoxr7b" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_ecustom--RevenuesExcludingOtherRevenue_zIx3RMBdmG8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,484</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,659</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">31,143</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueNotFromContractWithCustomerOther_z4RlIcbCgDqi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">496</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestExpense_zEA3GbSHgWzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_zVw7Mk13lAtg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationAndAmortization_zqsa6dVNmGEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,493</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_zrNo64joulid" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(147</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_zrmSCkVVwyM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,245</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherOperatingIncomeExpenseNet_zSJP3Lndlold" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,107</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_zVKMA4WMvNpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,467</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_zm2TANlzNdEa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,634</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,493</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,359</td><td style="text-align: left"> </td></tr> </table>

CY2022Q2

swkh

Revenues Excluding Other Revenue

RevenuesExcludingOtherRevenue

6942000

usd

CY2022Q2

us-gaap

Interest Expense

InterestExpense

80000

usd

CY2022Q2

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1480000

usd

CY2022Q2

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

626000

usd

CY2022Q2

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-991000

usd

CY2022Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

182000

usd

CY2022Q2

us-gaap

Profit Loss

ProfitLoss

565000

usd

CY2021Q2

swkh

Revenues Excluding Other Revenue

RevenuesExcludingOtherRevenue

22266000

usd

CY2021Q2

us-gaap

Interest Expense

InterestExpense

94000

usd

CY2021Q2

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1542000

usd

CY2021Q2

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

811000

usd

CY2021Q2

swkh

Change In Fair Value Of Acquisitionrelated Contingent Consideration

ChangeInFairValueOfAcquisitionrelatedContingentConsideration

-147000

usd

CY2021Q2

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

3360000

usd

CY2021Q2

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

892000

usd

CY2021Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

3528000

usd

CY2021Q2

us-gaap

Profit Loss

ProfitLoss

13970000

usd

swkh

Revenues Excluding Other Revenue

RevenuesExcludingOtherRevenue

17593000

usd

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

480000

usd

us-gaap

Interest Expense

InterestExpense

160000

usd

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

3381000

usd

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

1330000

usd

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

6178000

usd

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-1712000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1269000

usd

us-gaap

Profit Loss

ProfitLoss

4043000

usd

swkh

Revenues Excluding Other Revenue

RevenuesExcludingOtherRevenue

31143000

usd

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

496000

usd

us-gaap

Interest Expense

InterestExpense

239000

usd

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

3090000

usd

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

2493000

usd

swkh

Change In Fair Value Of Acquisitionrelated Contingent Consideration

ChangeInFairValueOfAcquisitionrelatedContingentConsideration

-147000

usd

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

6245000

usd

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

2107000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

4467000

usd

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
swkh-20220630_cal.xml	Edgar Link	unprocessable
0001552781-22-000529-index-headers.html	Edgar Link	pending
0001552781-22-000529-index.html	Edgar Link	pending
0001552781-22-000529.txt	Edgar Link	pending
0001552781-22-000529-xbrl.zip	Edgar Link	pending
e22387001.jpg	Edgar Link	pending
e22387_ex31-01.htm	Edgar Link	pending
e22387_ex31-02.htm	Edgar Link	pending
e22387_ex32-01.htm	Edgar Link	pending
e22387_ex32-02.htm	Edgar Link	pending
e22387_swkh-10q.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
e22387_swkh-10q_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
swkh-20220630.xsd	Edgar Link	pending
swkh-20220630_def.xml	Edgar Link	unprocessable
swkh-20220630_lab.xml	Edgar Link	unprocessable
swkh-20220630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SWKH
SWK Holdings Corp Stock $swkh

2022 Q3 Form 10-Q Financial Statement

#000155278122000529 Filed on August 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWKH SWK Holdings Corp Stock $swkh

2022 Q3 Form 10-Q Financial Statement

#000155278122000529 Filed on August 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWKH
SWK Holdings Corp Stock $swkh